Imperial College London


Faculty of MedicineDepartment of Infectious Disease

Emeritus Professor of Immunology



+44 (0)20 3315 8257f.gotch




Mrs Julie James +44 (0)20 3315 8258




J 2 12Chelsea and Westminster HospitalChelsea and Westminster Campus





Publication Type

198 results found

Krishna SK, Meys R, Purdie KJ, de Koning MN, Bardhan A, Gotch FM, Quint WG, Harwood C, Bunker CBet al., 2010, Carcinoma in-situ of the penis and beta-HPV types, Annual Meeting of the Society-for-Investigative-Dermatology, Publisher: NATURE PUBLISHING GROUP, Pages: S27-S27, ISSN: 0022-202X

Conference paper

Meys R, Purdie KJ, de Koning MN, Krishna SK, Kamp M, Nelson M, Asboe D, Hawkins DA, Quint WG, Gotch FM, Harwood C, Bunker CBet al., 2010, The HPV profile of cutaneous warts in HIV infected patients, Annual Meeting of the Society-for-Investigative-Dermatology, Publisher: NATURE PUBLISHING GROUP, Pages: S125-S125, ISSN: 0022-202X

Conference paper

Meys R, Gotch FM, Bunker CB, 2010, Human papillomavirus in the era of highly active antiretroviral therapy for human immunodeficiency virus: an immune reconstitution-associated disease?, BRITISH JOURNAL OF DERMATOLOGY, Vol: 162, Pages: 6-11, ISSN: 0007-0963

Journal article

Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, Kaltsidis H, Cashin-Cox M, Anjarwalla I, Steel A, Higgs C, Pozniak A, Piechocka-Trocha A, Wong J, Anzala O, Karita E, Dally L, Gotch F, Walker B, Gilmour J, Hayes Pet al., 2010, Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates, J Infect Dis, Vol: 201, Pages: 720-729, ISSN: 1537-6613

Journal article

Robey RC, Mletzko S, Gotch FM, 2010, The T-Cell Immune Response against Kaposi's Sarcoma-Associated Herpesvirus., Adv Virol, Vol: 2010, ISSN: 1687-8639

Kaposi's sarcoma-associated herpesvirus (KSHV) is the aetiological agent of Kaposi's sarcoma (KS), the most frequently arising malignancy in individuals with untreated HIV/AIDS. There are several lines of evidence to indicate that Kaposi's sarcoma oncogenesis is associated with loss of T-cell-mediated control of KSHV-infected cells. KSHV can establish life-long asymptomatic infection in immune-competent individuals. However, when T-cell immune control declines, for example, through AIDS or treatment with immunosuppressive drugs, both the prevalence of KSHV infection and the incidence of KS in KSHV carriers dramatically increase. Moreover, a dramatic and spontaneous improvement in KS is frequently seen when immunity is restored, for example, through antiretroviral therapy or the cessation of iatrogenic drugs. In this paper we describe the current state of knowledge on the T-cell immune responses against KSHV.

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: id=00166452&limit=5&person=true&page=10&respub-action=search.html